微信直播

WCLC 2017专访 | Dr. Howard Jack West:下一代测序或将成肺癌诊治“标配”

Published at: 2015年第1卷第S1期

AME
关键词:

编者按:2017年10月15日-18日,第十八届世界肺癌大会(WCLC 2017)于日本横滨成功举办。置身于全球颇负盛名的肺癌和其他胸部恶性肿瘤的多学科肿瘤学顶尖会议中,不仅可以获知该领域最新的研究成果和医疗技术方面的新进展,还可以与来自世界各地的知名专家进行互动交流。这次会议中,AME出版社十分荣幸地采访了来自西雅图瑞典癌症研究所(Seattle’s Swedish Cancer Institute)——太平洋西北地区最大的私人肿瘤中心的专家Dr. Howard Jack West

人物聚焦:Howard Jack West

Dr. Howard Jack West is a medical oncologist and medical director of the Thoracic Oncology and Genitourinary Oncology Programs at Seattle’s Swedish Cancer Institute, the largest private oncology center in the Pacific Northwest. His work fighting lung cancers, including pleural mesothelioma, as well as prostate, bladder, testicular and other cancers has earned him repeated recognition as a “Top Doctor” by Seattle Metropolitan Magazine, an honor voted on by his medical peers. Dr. West is founder of the Global Resource for Advancing Cancer Education (GRACE).

After earning his bachelor’s degree from Princeton University in 1990, Dr. West received a prestigious Fulbright Scholarship to the University of Cambridge in the United Kingdom, where he received a master’s degree in experimental biology. He returned to the U.S. to attend Harvard Medical School, where he completed research as a medical student fellow of the Howard Hughes Medical Institute. After earning his MD magna cum laude in 1996, Dr. West trained at Harvard’s Brigham and Women’s Hospital in Boston for an internal medicine internship and residency. He then moved to Seattle to train in medical oncology at the University of Washington/Fred Hutchinson Cancer Research Center, where he developed his expertise in lung cancer and mesothelioma.

图. Dr. Howard Jack West与AME编辑合影

作为WCLC 2017邀请的杰出演讲嘉宾,Dr. West就EGFR突变阳性晚期非小细胞肺癌(NSCLC)的获得性耐药进行了前后三次的分享。他分享道,靶点MET可能会逐渐被识别,且与临床密切相关。虽然这一领域还有很多未知需要去探索,但总体来说,前景相当乐观,我们的探索必将对目前的治疗方案带来变革。

就像最近这些年来我们取得的进步一样。回首过去,20年前的肺癌研究,似乎真的不那么讨喜。关注的人少,新进展不多,病人状况不好,患者得了肺癌几乎就意味着即将走到生命的尽头了。Dr. West表示,身边的朋友同事都对他的职业选择十分惊讶,但当他看到肺癌患者从当年的仅能存活几个月,到后来的1年以上,再到现在能存活好几年,其中的动力就不言而喻了。这对于病人来说无疑不是一场漂亮的胜仗,而对于整个领域的发展,更是质的飞跃。

另外,对于分子标记物是否将会取代化疗成为晚期NSCLC的一线治疗这一说法,Dr. West并不完全认同。在Dr. West看来,人们一直致力于研究并向往更精准的医学,认为一般治疗会存在局限性,而更偏向于精准的靶向治疗。然而,不同的地区,肺癌的种类及影响因素会有所差异。所以,化疗仍存在着广泛的用途,但在今后的发展中,精准医学将会展示出更大的价值。

此外,Dr. West还谈到了他对未来NSCLC的诊断和研究的看法,他认为肺癌领域发展日新月异,随着越来越多的驱动突变被识别出来,未来最大的变化可能是下一代测序(NGS)或将成为肺癌诊治的“标配”。

采访问题

  1. As a distinguished invited speaker for the WCLC 2017, you had an excellent presentation, which was well received by the audience. Would you like to summarize some main points to share with us?

  2. Some people may say, there will be a day when molecular markers finally replace first line treatment option for advanced Non-Small Cell Lung Cancer. What is your opinion on it? 

  3. As an outstanding expert in the field, would you like to share your opinions/suggestions with Chinese experts on future studies on diagnosis and treatment of Non-Small Cell Lung Cancer?

  4. Along the way to be an excellent researcher, would you like to share with us any stories about it? What encourage you to choose the career/field?

更多精彩内容,欢迎观看视频。


采访编辑:凌晨,AME Publishing Company

撰写编辑:冯雁萍、Bella Poon,AME Publishing Company

学术审核:张开平,AME Publishing Company

责任编辑:陈媛玲,AME Publishing Company

comments powered by Disqus

附件